Assembly Biosciences (NASDAQ:ASMB - Get Free Report) released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts' consensus estimates of ($2.01) by $0.84, Zacks reports. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The company had revenue of $9.42 million during the quarter, compared to analysts' expectations of $7.41 million.
Assembly Biosciences Price Performance
Shares of NASDAQ ASMB traded up $0.49 during mid-day trading on Thursday, hitting $12.60. The company had a trading volume of 6,427 shares, compared to its average volume of 25,709. Assembly Biosciences has a 1-year low of $7.75 and a 1-year high of $19.93. The company has a market capitalization of $96.27 million, a PE ratio of -1.99 and a beta of 0.49. The business's 50-day simple moving average is $10.62 and its 200 day simple moving average is $13.47.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on ASMB shares. StockNews.com downgraded Assembly Biosciences from a "buy" rating to a "hold" rating in a report on Monday, March 24th. Guggenheim started coverage on Assembly Biosciences in a research report on Tuesday, March 25th. They set a "buy" rating and a $31.00 target price for the company. Finally, HC Wainwright reiterated a "neutral" rating on shares of Assembly Biosciences in a report on Monday, March 24th.
Get Our Latest Stock Analysis on Assembly Biosciences
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Recommended Stories
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
